alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 99
----------




                       SECTION 906 CERTIFICATION
                       -------------------------



     The following statement is provided by the undersigned to accompany
the foregoing Report on Form 10-Q pursuant to Section 906 of the Sarbanes-
Oxley Act of 2002 and shall not be deemed filed pursuant to any provision
of the Exchange Act of 1934 or any other securities law:

     Each of the undersigned certifies that the foregoing Report on
Form 10-Q fully complies with the requirements of Section 13(a) of the
Securities Exchange Act of 1934 (15 U.S.C. 78m) and that the information
contained in the Form 10-Q fairly presents, in all material respects, the
financial condition and results of operations of ARVIDA/JMB PARTNERS, L.P.



                                  By:  Arvida/JMB Managers, Inc.
                                       The General Partner




                                       /s/   Gary Nickele
                                       ------------------------------
                                       Gary Nickele
                                       Chief Executive Officer




                                       /s/   Gailen J. Hull
                                       ------------------------------
                                       Gailen J. Hull
                                       Chief Financial Officer and
                                       Principal Accounting Officer
**Exhibit31.1**

CERTIFICATIONS

I, Alan Kiraly, certifythat:

1. I have reviewed thisquarterly report on Form 10-Q of Spescom Software Inc.;

2. Based on my knowledge,this quarterly report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, inlight of the circumstances under which such statements were made, notmisleading with respect to the period covered by this quarterly report;

3. Based on my knowledge,the financial statements, and other financial information included in thisquarterly report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, andfor, the periods presented in this quarterly report;

4. The registrant’s othercertifying officer(s) and I are responsible for establishing and maintainingdisclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)) for the registrant and have:

a) designed suchdisclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this quarterly report is being prepared;

b) evaluated theeffectiveness of the registrant’s disclosure controls and procedures andpresented in this quarterly report our conclusions about the effectiveness ofthe disclosure controls and procedures, as of the end of the period covered bythis quarterly report based on such evaluation; and

c) disclosed in thisquarterly report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (theregistrant’s fourth fiscal quarter in the case of an annual report) that hasmaterially affected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and

5. The registrant’s othercertifying officer(s) and I have disclosed, based on our most recent evaluationof internal control over financial reporting, to the registrant’s auditors andthe audit committee of the registrant’s board of directors (or personsperforming the equivalent functions):

a) all significantdeficiencies and material weaknesses in the design or operation of internalcontrol over financial reporting which are reasonably likely to adverselyaffect the registrant’s ability to record, process, summarize and reportfinancial information; and

b) any fraud, whether ornot material, that involves management or other employees who have asignificant role in the registrant’s internal control over financial reporting
| Dated:   February 14, 2007 |   |   |
|--------------------------------------|--------|--------|
|                                 |   |   |
| /s/ Alan Kiraly                      |   |   |
| Alan Kiraly                          |   |   |
|                                 |   |   |
| Chief Executive  Officer             |   |   |

 

25

----
§ 516.1012 Fuzapladib. ( a ) *Specifications.* The drug is provided as a powder for injection that is reconstituted with 3.5 milliliter (mL) of provided diluent to a final concentration of 4 milligrams (mg) fuzapladib sodium per mL.
( b ) *Sponsor.* See No. 064642 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Administer at a dosage of 0.4 mg (0.1 mL) per kilogram of body weight once daily for 3 consecutive days by intravenous (IV) injection over 15 seconds to 1 minute.
( 2 ) *Indications for use in dogs.* For the management of clinical signs associated with acute onset of pancreatitis in dogs.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal law to use this product other than as directed in the labeling.
[88 FR 16546, Mar. 20, 2023]
§ 522.1290 Luprostiol. ( a ) *Specifications.* Each milliliter of solution contains 7.5 milligrams (mg) luprostiol.
( b ) *Sponsor.* See No. 051311 in § 510.600(c) of this chapter.
( c ) *Special considerations.* Labeling shall bear the following statements: *Warning:* Women of childbearing age, asthmatics, and persons with bronchial and other respiratory problems should exercise extreme caution when handling this product. In the early stages, women may be unaware of their pregnancies. Luprostiol is readily absorbed through the skin and can cause abortion and/or bronchiospasms. Direct contact with the skin should therefore be avoided. Accidental spillage on the skin should be washed off immediately with soap and water.
( d ) *Conditions of use in horses* — ( 1 ) *Amount.* 7.5 mg by intramuscular injection.
( 2 ) Indications for use. For estrus control and termination of pregnancy in mares.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian. Do not use in horses intended for human consumption.
[55 FR 1185, Jan. 12, 1990, as amended at 56 FR 50653, Oct. 8, 1991; 60 FR 55659, Nov. 2, 1995; 61 FR 66582, Dec. 18, 1996; 74 FR 25146, May 27, 2009]
Editorial Note on Part 172
Editorial Note: Nomenclature changes to part 172 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

§ 172.490 Yellow prussiate of soda. ( a ) The food additive yellow prussiate of soda (sodium ferrocyanide decahydrate; Na4Fe(CN)6·10H2O contains a minimum of 99 percent by weight of sodium ferrocyanide decahydrate.
( b ) The additive is used or intended for use as an anticaking agent in salt and as an adjuvant in the production of dendritic crystals of salt in an amount needed to produce its intended effect but not in excess of 13 parts per million calculated as anhydrous sodium ferrocyanide.
[42 FR 14491, Mar. 15, 1977, as amended at 58 FR 17098, Apr. 1, 1993]
SUPREME COURT OF THE STATE OF NEW YORK

Appellate Division, Fourth Judicial Department

689 

KA 15-00418 

PRESENT: CENTRA, J.P., LINDLEY, CURRAN, TROUTMAN, AND SCUDDER, JJ. 

 

THE PEOPLE OF THE STATE OF NEW YORK, RESPONDENT, 

V MEMORANDUM AND ORDER

JOHANNES HIRAM, DEFENDANT-APPELLANT.

 

THE LEGAL AID BUREAU OF BUFFALO, INC., BUFFALO (DEBORAH K. JESSEY OF

COUNSEL), FOR DEFENDANT-APPELLANT.

MICHAEL J. FLAHERTY, JR., ACTING DISTRICT ATTORNEY, BUFFALO (MATTHEW

B. POWERS OF COUNSEL), FOR RESPONDENT. 

 

Appeal from an order of the Supreme Court, Erie County (John L.

Michalski, A.J.), entered January 21, 2015. The order determined that

defendant is a level two risk pursuant to the Sex Offender

Registration Act. 

It is hereby ORDERED that the order so appealed from is

unanimously affirmed without costs.

Memorandum: Defendant appeals from an order determining that he

is a level two risk under the Sex Offender Registration Act

(Correction Law § 168 et seq.). Contrary to defendant’s contention,

Supreme Court properly assessed 15 points under risk factor 9 for his

nonviolent felony criminal history. That assessment is supported by

the reliable hearsay contained in the case summary (see People v

Thompson, 66 AD3d 1455, 1456, lv denied 13 NY3d 714; People v Ramos,

41 AD3d 1250, 1250, lv denied 9 NY3d 809; see generally People v

Mingo, 12 NY3d 563, 573), and defendant’s criminal history report (see

People v Palmer, 68 AD3d 1364, 1366; People v Mann, 52 AD3d 884, 886),

which establish that defendant committed a felony in the State of

Texas. “Although given an opportunity to discover and present

evidence on the matter . . . defendant adduced nothing in opposition

to those materials” (People v Wroten, 286 AD2d 189, 199, lv denied 97

NY2d 610).

We further conclude that the court properly assessed 10 points

under risk factor 12 based on defendant’s failure to accept

responsibility. Although defendant pleaded guilty to attempted sexual

abuse in the first degree (see Penal Law §§ 110.00, 130.65 [3]), and

stated that he was sorry and “never, never wants this to happen

again[,]” he denied that he touched the 10-year-old victim’s vagina

and also denied that his actions were motivated by sexual desire. 

Defendant’s denials, however, are in direct contradiction to his
-2- 689 

KA 15-00418 

guilty plea of attempted sexual abuse in the first degree (see

§§ 130.00 [3]; 130.65 [3]). Defendant’s “contradictory statements,

considered together, do not reflect a ‘genuine acceptance of

responsibility’ as required by the risk assessment guidelines

developed by the Board [of Examiners of Sex Offenders]” (People v

Noriega, 26 AD3d 767, 767, lv denied 6 NY3d 713 [internal quotation

marks omitted]). Finally, defendant’s contention that the People

failed to present clear and convincing evidence that he in fact

touched the victim’s vagina is raised for the first time on appeal and

is thus not preserved for our review (see People v Smith, 17 AD3d

1045, 1045, lv denied 5 NY3d 705).

Entered: September 30, 2016 Frances E. Cafarell

Clerk of the Court
OFFICE OF THE ATTORNEY GENERAL OF TEXAS AUSTIN

Honorable X. J. Townsend county Attorney Angellne cousitg lAmal, Texas Dear Sir: Opinion NO. O-7507 Be: I8 the presenoe

This acknowledges recei date whioh rsada:

county Attorney- -i&act to be wher,inveetiga1 violations or quallfled for the oath of investigating wltmo~~ 5. code of Crlalnal Prooedure, 8hte8 thet andjuror's oath la that *the Stete'a oounowe* and your own, you shall keep eecret.m 367b, C. C. P., whioh provides for the 

### l ppolntment of grand Jury bailiris, m&es a portion or said balliff'e oath thet 'you will keep eooret,the prooeedlngs of the grand jury.*iionortible ii. 3. ‘i’owneand, pa,:e 2

Art. 336, c. c. E., provides for the oath TVbe takeuby BwitueseVW testifiesbefore agrand jury. h portion of said oath la that *you will keep eeoret all yrooeodlnge of the greud jury.”Art. 375, C. C. P., provides that “the attorney repressntlng the State maygo befom the grend jury at any time exoept whenXhoy are dlnouoalng the propriety of finding an lndlotnbmnt or voting upon the B(UPB.~ In view of the preoedlng statutes pertalnlng to the aeorsoy of **grand** jurs prooeedlngs, **and** In view of the statute apeolfioallg .authorltiing the appearanoe befor@ the grand jury or the attorney mpreaontlng ~thaState, it would seein that a apeoiflo le&slatlve authorlsatian would be neoemury to allow the Xetrlot and County At~rne&Gtoot, aa auoh, to attend eeaaionr of a grand jury. Slnoe we find no law authorizing their preaenoe et eaid weeions, we oonolude that said attorney8 am unauthorized pelraona at thoee aeaalona. Although we find no !l’exaaoaaea In point, in i’eople V. Lunson, 150M. 6. 280, the SupremoCourt of Illlnole aaid:

*It ie a rundaaectal element of a grand jury lmeaTo thie end the law refuses

-A grand jury Is organlsed for the purpose or proteoting oltisenr from unfounded aocuaation es well aa lnveafigating ehugom of ori~ and returning lndlot- -AtO thema. By mawn or the faot that the purpow of au& pra#eotlanmaybe largely forfeited where the lnverfigafiona of the grand jury beoomaknown, the work of that body ia surrounded by eecreoy and Vb8Wd with wlamnlty. Out of thaeo vtewr hae ariaen the rule that unauthofiierd Deraonomeynot be allowed to attend upon their lnve8tlgatlona.~ Iemphdsfi added)

In View of the toregoing it i# the oplnlon of thim department that the pra8enoe of the Dlatrlot and County Attornep8-ileot, aa311

Louorobla ii. J. ,i'ownsond, pace 3 euch,in rrgrand jury eeesion,wherein lnvestiC;~tions of ori~- ill vlolationeam belnbzwde, is unauthorized and ehould not bepermitted.

lit, trust that the foregoingfully anewerayour questIon. Youre vary truly,

Williamii.Stepp

Aaaietant
<PAGE>   1
                                                                    EXHIBIT 23.1

                       CONSENT OF INDEPENDENT ACCOUNTANTS

We hereby consent to the incorporation by reference in this Registration
Statement on Form S-4 of ARIS Corporation of our report dated January 28, 1999,
relating to the financial statements of ARIS Corporation, which appears in such
Registration Statement on Form S-4 filed on August 5, 1999. We also consent to
the application of such report to the Financial Statement Schedule for the three
years ended December 31, 1998 when such schedule is read in conjunction with
the financial statements referred to in our report. The audits referred to in
such report are also included in this schedule. We also consent to the
references to PricewaterhouseCoopers LLP under the headings "Experts" and
"Selected Financial Data" in such Registration Statement on Form S-4 filed
pursuant to Rule 462(b). However, it should be noted that PricewaterhouseCoopers
LLP has not prepared or certified such "Selected Financial Data."


PRICEWATERHOUSECOOPERS LLP

PricewaterhouseCoopers LLP
Seattle, Washington
August 27, 1999
§ 1312.28 Distribution of export declaration. ( a ) The exporter must ensure that an official record of the export declaration (available from the DEA Diversion Control Division secure network application after the Administration issues a transaction identification number) accompanies the shipment of controlled substances to its destination.
( b ) The exporter, or their agent, must submit an official record of the export declaration and/or required data concerning the export transaction to a customs officer at the port of export in compliance with all export control requirements of agencies with export control authorities under the Act or statutory authority other than the Controlled Substances Import and Export Act.
( c ) The exporter must maintain an official record of the export declaration and return information (both available from the Diversion Control Division secure network application after the Administration issues a transaction identification number) required pursuant to § 1312.27(d) as his or her record of authority for the exportation, in accordance with part 1304 of this chapter.
[81 FR 97035, Dec. 30, 2016]
EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, I, David H. Thompson, Secretary and Chief Financial Officer, certify that:

1.

To my knowledge, this report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.

To my knowledge, the information in this report fairly presents, in all material respects, the financial condition and results of operations of International Absorbents Inc.



|                    |                                                                             
|------------------- | ----------------------------------------------------------------------------
|Date: June 11, 2009 | /s/ DAVID H. THOMPSON
David H. ThompsonSecretary and Chief Financial Officer
Notes from Meeting with HDMA

Attended by:

HDMA Staff: Allison Tuszynski and Anita Ducca

Other Staff: Tish Pahl, OFW Law

Bob Fensterheim, RegNet Environmental Services

EPA Staff: Mary Jackson and Kristin Fitzgerald

Date: January 7, 2014

EPA met with representatives from the Healthcare Distribution Management Association 

(HDMA), their outside counsel and consultant. They discussed their members’ roles in the 

distribution and reverse distribution of pharmaceuticals. They also discussed the recently 

enacted law, the Drug Quality and Security Act (DQSA). They indicated that in 2010, 

approximately 2% of pharmaceuticals are returned to reverse distributors.
### Water in the Coconino sandstone for the Snowflake-Hay Hollow area, Navajo County, Arizona

By: Phillip W. Johnson

                            https://doi.org/10.3133/wsp1539S

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plates:                               - **Plate 1**                            (pdf)
  - **Plate 2**                            (pdf)
  - **Plate 3**                            (pdf)
  - **Plate 4**                            (pdf) 
- NGMDB Index Page:  **National Geologic Map Database Index Page**                            (html)
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

No abstract available.

#### Study Area

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
<PAGE>   1

                                                                    EXHIBIT 23.3


                         CONSENT OF INDEPENDENT AUDITORS


As independent public accountants and auditors, we hereby consent to the
reference to our firm under the caption "Experts" and to the incorporation by
reference in the Prospectus/Joint Proxy Statement and in this United Security
Bancorporation Registration Statement on Form S-4 of our report dated January
29, 1998 included in United Security Bancorporation's Annual Report on Form 10-K
for the year ended December 31, 1997.


/s/ MOSS ADAMS LLP

Everett, Washington
December 15, 1998
<PAGE>   1


                                                                    EXHIBIT 23.1

                    CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS

We consent to the incorporation by reference in this Registration Statement of
Getty Images, Inc. on Form S-3 of our report dated March 31, 1999 of our audits
of the consolidated financial statements and financial statement schedules of
Getty Images, Inc. and subsidiaries and of its predecessor, Getty Communications
plc and subsidiaries, appearing in the Annual Report on Form 10-K of Getty
Images, Inc. We also consent to the reference to our firm under the caption
"Experts".



                                        /s/ PricewaterhouseCoopers


PricewaterhouseCoopers
London
May 21, 1999
EXHIBIT 23.1

INDEPENDENT AUDITORS' CONSENT

We  consent  to the  inclusion  in  this  Amendment  No.  1 to the  Registration
Statement on Form S-1 of our report dated November 23, 1999, on our audit of the
financial statements of Urban Cool Network, Inc. as of December 31, 1998 and for
the period  January 23, 1998  (inception)  through  December 31, 1998 and to the
reference of our firm under the caption "Experts".

Richard A. Eisner & Company, LLP

New York, New York
January 18, 2000
Exhibit








Exhibit 10.1


SYNOVUS FINANCIAL CORP.
Board of Directors Compensation
(Effective April 20, 2017)




	
					
	 
	 
	 
	 

	Cash Compensation
	 
	 
	

	 

	 
	 
	 
	 

	Annual Board Retainer
	$
	50,000
	

	 

	 
	 
	 
	

	 

	Annual Board Committee Member Retainers:
	 
	 
	

	 

	Audit Committee
	$
	15,000
	

	 

	Compensation Committee
	$
	10,000
	

	 

	Corporate Governance and Nominating Committee
	$
	10,000
	

	 

	Risk Committee
	$
	10,000
	

	 

	 
	 
	 
	

	 

	Annual Committee Chair Retainers:**
	 
	 
	

	 

	Audit Committee
	$
	15,000
	

	 

	Compensation Committee
	$
	10,000
	

	 

	Corporate Governance and Nominating Committee
	$
	10,000
	

	 

	Risk Committee 
	$
	10,000
	

	 

	 
	 
	 
	 

	Annual Lead Director Retainer
	$
	20,000
	

	 




	
		
	**
	Note: The committee chair will receive both an annual committee member retainer and an annual committee chair retainer.




	
					
	Equity Compensation
	 
	 
	

	 

	 
	 
	 
	 

	An award of $75,000 in restricted stock units, which becomes fully vested and transferable upon the earlier to occur of the (x) completion of three years of service and (y) date the holder reaches retirement age pursuant to the Company's Corporate Governance Guidelines.
	 

	 
	 
	 
	

	 

	Director Stock Purchase Plan
	 
	 
	

	 

	 
	 
	 
	

	 

	Annual maximum company cash contribution per director participant to company-sponsored open market stock purchase plan, with company’s contribution equal to 15% of director participant’s cash contribution, subject to annual maximum contribution limit by director of $20,000
	$
	3,000